Brain Cancer

Pembrolizumab Monotherapy Elicits Responses in Patients With Advanced Rare Cancers

March 20, 2020

Treatment with pembrolizumab demonstrated antitumor activity along with tolerable toxicity in patients with 4 different rare and hard-to-treat malignancies, according to results from a phase II study led by The University of Texas MD Anderson Cancer Center researchers and published in the Journal for ImmunoTherapy of Cancer.

Bevacizumab Biosimilar Under Review by FDA

March 09, 2020

The FDA has accepted a Biologics License Application for MYL-1402O, a proposed biosimilar to bevacizumab, according to a press release from co-developers Biocon and Mylan. The BLA is seeking approval for the biosimilar as a treatment for multiple types of cancer and the FDA has set an action date goal of December 27, 2020, for a decision on the BLA.

First CLTX-Directed CAR T-Cell Therapy Expands Landscape of Tumor-Selective CAR T cells in Glioblastoma

March 09, 2020

The first chimeric antigen receptor T-cell therapy to utilize chlorotoxin to direct T cells to target cancer cells in the brain has been developed at the City of Hope and demonstrated antitumor activity in a preclinical study. Based on these findings, the first-in-human clinical trial has opened enrollment at City of Hope for patients with recurrent or progressive glioblastoma.

Novel Coronavirus Impedes Travel Among Oncologists, But They Remain Undaunted

March 07, 2020

As the new coronavirus disease 2019 creates problems internationally, health-wise and economically, it is also becoming a cause for concern throughout the oncology community.

A Look Back at FDA News from February 2020

March 04, 2020

In February 2020, the FDA gave indications to multiple therapies meant for treatment of solid tumor and hematologic malignancies. FDA action included 10 Priority Reviews, 2 Breakthrough Therapy designations, and 2 Fast Track designations.

ACCC Creates Resources for Multidisciplinary Practices to Prepare for Growing Geriatric Cancer Population

February 25, 2020

To help clinicians cope with an increasing number of geriatric patients with cancer, the Association of Community Cancer Centers is address­ing this problem with a 2-pronged approach that focuses on the delivery of care and diagnostic assessment.

Phase II Trial Demonstrates Benefit for Patients With Recurrent Meningiomas

February 01, 2020

Patients with aggressive meningiomas presented with clinical and radiological activity when receiving a combination of everolimus and octreotide in the single-arm phase II CEVOREM trial.

New Combination Builds Upon Existing Therapies for Anaplastic Astrocytoma

February 01, 2020

Arati Desai, MD, explains how the results from the phase III STELLAR trial will enhance knowledge of anaplastic astrocytoma.

STELLAR Trial Explores Potential Treatment Options for Anaplastic Astrocytoma

February 01, 2020

In an interview with Targeted Oncology, Arati Desai, MD, co-director of the University of Pennsylvania Brain Tumor Cancer Program Center, assistant professor of clinical medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, discussed the implications of the STELLAR trial, the role of eflornithine, and how IDH1/2 mutational status affects outcomes in patients with anaplastic astrocytomas.

First Randomized Clinical Trial Evaluating Geriatric Assessment Reveals High Satisfaction With Communication About Aging-Related Concerns

January 18, 2020

Integrating a geriatric assessment into the care of older adults who are receiving cancer treatment in communi­ty oncology practices improves patient and caregiver satisfaction and encourages commu­nication about aging-related concerns, accord­ing to results of a clinical trial that enrolled 541 patients with advanced cancer.